menu search

Biocardia (bcda) up on plans for second heart failure study

BioCardia (BCDA) completes enrollment in a pivotal phase III study on its cardiamp cell therapy for the...

October 12, 2023, 12:47 pm

Biocardia (bcda) dips 26% on flunking heart failure study

Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its cardiamp...

September 6, 2023, 12:01 pm

Biocardia announces interim efficacy results in phase iii pivotal cardiamp cell therapy heart failure trial

SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

September 5, 2023, 11:15 am

Biocardia shares slide on disappointing interim data from heart therapy trial

BioCardia shares fell more than 20% in pre-market trade on Tuesday after the biopharmaceutical firm revealed that its Phase 3 trial of ...

September 5, 2023, 9:31 am

Biocardia announces fda completes review of proposed adaptive statistical analysis design for ongoing cardiamp cell therapy in heart failure pivotal study

SUNNYVALE, Calif., June 20, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the ...

June 20, 2023, 9:14 pm

Biocardia announces timing of the next data safety monitoring board meeting for the cardiamp cell therapy in heart failure pivotal study

SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the t...

May 23, 2023, 11:00 am

Safety board recommends biocardia's heart failure cell therapy to continue unchanged

The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc's (NASDAQ: BCDA) ongoing Phase 3 ...

February 14, 2022, 10:29 am

Safety board recommends biocardia's heart failure cell therapy to continue unchanged

The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc's (NASDAQ: BCDA) ongoing Phase 3 ...

February 14, 2022, 10:29 am

Safety board recommends biocardia's heart failure cell therapy to continue unchanged

The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc's (NASDAQ: BCDA) ongoing Phase 3 ...

February 14, 2022, 10:29 am

Why are biocardia shares trading higher today?

The FDA has granted Breakthrough Device Designation for BioCardia Inc's  BCDA cardiamp Cell Therapy...

February 3, 2022, 2:53 pm

Why are biocardia shares trading higher today?

The FDA has granted Breakthrough Device Designation for BioCardia Inc's  BCDA cardiamp Cell Therapy...

February 3, 2022, 2:53 pm

Why are biocardia shares trading higher today?

The FDA has granted Breakthrough Device Designation for BioCardia Inc's  BCDA cardiamp Cell Therapy...

February 3, 2022, 2:53 pm


Search within

Pages Search Results: